Heron Therapeutics (HRTX) Price to Book (2011 - 2026)

Heron Therapeutics (HRTX) has reported Price to Book for 16 consecutive years, with 11.82 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Price to Book rose 201.52% year-over-year to 11.82; the trailing twelve-month figure through Jun 2026 stood at 11.82 (up 201.52% YoY), and the FY2025 full-year result was 17.08, up 346.94% from the prior year.
• Price to Book eased to 11.82 in Q2 2026 per HRTX's latest filing, from 16.57 in the prior quarter.
• Across five years, Price to Book topped out at 24.47 in Q1 2022 and bottomed at 15.82 in Q1 2023.
• Historically, Price to Book has averaged 1.07 across 5 years, with a median of 6.24 in 2023.
• The sharpest annual moves came in 2024 and 2025: Price to Book tumbled 236.62% in 2024, then surged 346.94% in 2025.
• Over 5 years, Price to Book stood at 21.95 in 2022, then sank by 134.26% to 7.52 in 2023, then grew by 8.02% to 6.92 in 2024, then soared by 346.94% to 17.08 in 2025, then tumbled by 30.81% to 11.82 in 2026.
• According to Business Quant data, Price to Book over the past three periods registered 11.82, 16.57, and 17.08 for Q2 2026, Q1 2026, and Q4 2025 respectively.